Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Exosomal CircGANAB promotes cancer progression and immunotherapy resistance by degrading interacting RNAs and limiting T cell infiltration in pancreatic ductal adenocarcinoma.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2026

Same author

CircZBTB44-Encoded Peptide ZBTB44-342aa Alleviates Aortic Valve Calcification Via cGAS-STING Inhibition.

Circulation research·2026

Same author

Corrigendum to "B cell CLL/lymphoma 6 member B inhibits hepatocellular carcinoma metastases in vitro and in mice" [Cancer Lett. 355 (2014) 192-200].

Cancer letters·2025

Same author

Trimethylamine N-oxide aggravates human aortic valve interstitial cell inflammation by regulating the macrophages polarization through a N6-methyladenosine-mediated pathway.

Atherosclerosis·2025

Same author

Interleukin-37 attenuates aortic valve lesions by inhibiting N6-methyladenosine-mediated interleukin-1 receptor-associated kinase M degradation.

Cardiovascular research·2025

Same author

Dynamic roles of tumor-infiltrating B lymphocytes in cancer immunotherapy.

Cancer immunology, immunotherapy : CII·2025

Search research articles

Related Experiment Video

Updated: May 10, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Targeting long non-coding RNAs in cancers: progress and prospects.

Chi Han Li¹, Yangchao Chen

¹School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.

The International Journal of Biochemistry & Cell Biology

|June 11, 2013

Summary

Long non-coding RNAs (lncRNAs) play crucial roles in cancer development. Targeting these non-coding RNA molecules offers a promising new strategy for developing effective cancer therapies.

Keywords:

ANRIL ASO ATRA CRC CREB Cancer DM1 DsRNA EMT Epigenetics HCC HOTAIR HOX transcript antisense intergenic RNA HULC HamRz IRES LSCC LincRNA LncRNA Long non-coding RNA MALAT1 NAT NSCLC Nucleic acid drugs ORF PCGEM1 PCa RISC RNA interference RNA secondary structure RNAi RNAi silencing complex SELEX T-UCR TAR Therapeutic targets UTR all-trans retinoic acid antisense non-coding RNA in the INK4 locus antisense oligonucleotide cAMP-responsive element binding protein colorectal carcinoma double-stranded RNA epithelial–mesenchymal transition hammerhead ribozyme hepatocellular carcinoma highly up-regulated in liver cancer internal ribosomal entry site laryngeal squamous cell carcinoma long intergenic non-coding RNA long non-coding RNA metastasis associated lung adenocarcinoma transcript 1 myotonic dystrophy type 1 natural antisense transcript non-small cell lung carcinoma open reading frame prostate cancer prostate cancer gene expression marker 1 shRNA siRNA small hairpin RNA small interfering RNA systematic evolution of ligands by exponential enrichment transactivation response element transcribed ultraconserved region untranslated region

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Related Experiment Videos

Last Updated: May 10, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Area of Science:

Genomics and Molecular Biology
Cancer Research
RNA Biology

Background:

The human genome produces thousands of RNA transcripts, including long non-coding RNAs (lncRNAs) larger than 200 nucleotides.
lncRNAs, lacking protein-coding ability, are increasingly recognized for their significant roles in various biological functions, particularly in cancer development and progression.
Existing research highlights the involvement of specific lncRNAs in cancers, with targeting strategies showing inhibitory effects on malignant cells.

Purpose of the Study:

To discuss the fundamental characteristics of lncRNAs, including their synthesis, stability, and cellular functions.
To emphasize the unique properties of lncRNAs that dictate their molecular functions.
To explore the association between lncRNAs and cancer, and to illustrate the anticancer effects of modulating lncRNA levels and functions.

Main Methods:

Review and discussion of lncRNA characteristics, synthesis, stability, and functional roles.
Analysis of the association between lncRNAs and cancer development.
Exploration of established and novel therapeutic strategies for targeting lncRNAs in cancer treatment.

Main Results:

lncRNAs are implicated in cancer development and progression.
Modulating lncRNA levels and functions can induce anticancer effects.
lncRNAs represent potential therapeutic targets for cancer.

Conclusions:

lncRNAs possess unique properties that are critical for their molecular functions.
Targeting lncRNAs presents a promising avenue for novel cancer therapies, building on advances in nucleic acid-based drugs.
Further research into lncRNA targeting strategies is warranted for effective cancer treatment.